CYCC Stock Financial Analysis - Cyclacel Pharmaceuticals, Inc. (NasdaqCM) Stock

Overview

Cyclacel Pharmaceuticals, Inc., based in the United States, is a biopharmaceutical company primarily engaged in the development of innovative cancer therapies. Specializing in cell cycle biology, Cyclacel explores the unique properties of drugs affecting the cell cycle, aiming to halt the proliferation of cancer cells. Key projects include a portfolio of small molecule treatments targeting various cancer forms. A notable focus is on their lead candidate, sapacitabine, which is in late-stage trials for acute myeloid leukemia (AML) and other hematologic malignancies. The company combines these efforts with research into other cyclin-dependent kinase inhibitors and kinase inhibitors, seeking to enhance the efficacy and reduce the toxicity of chemotherapeutic agents. Cyclacel's strategy emphasizes precise patient selection in clinical trials to optimize outcomes and accelerate the path to potential regulatory approval.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is 0.01 MM.
The operating income for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -10.36 MM.
The net income for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -6.41 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	0.01	-10.36	-6.41
2025-03-31	0.01	-12.69	-8.35
2024-12-31	0.04	-12.00	-11.21
2024-09-30	0.07	-15.54	-13.43
2024-06-30	0.08	-20.20	-17.51
2024-03-31	0.45	-22.49	-19.70
2023-12-31	0.42	-25.45	-22.55
2023-09-30	0.39	-28.94	-24.70
2023-06-30	0.37	-28.56	-23.77
2023-03-31		-28.42	-22.89
2022-12-31		-27.66	-21.20
2022-09-30		-24.80	-18.64
2022-06-30		-24.88	-18.96
2022-03-31		-25.19	-19.52
2021-12-31		-22.39	-18.46
2021-09-30		-19.57	-16.40
2021-06-30		-16.14	-13.66
2021-03-31		-12.52	-10.70
2020-12-31		-10.64	-8.45
2020-09-30		-10.26	-7.95

Income Statement: EPS

The earnings per share basic for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -4.06.
The earnings per share diluted for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -4.06.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-4.06	-4.06
2025-03-31	-9.66	-9.66
2024-12-31	-502.46
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -8.73 MM.
The cash from financing activities for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is 7.14 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-8.73		7.14
2025-03-31	-10.75		11.55
2024-12-31	-7.99		7.82
2024-09-30	-10.54	0.00	7.21
2024-06-30	-11.51	0.00	7.16
2024-03-31	-9.73	0.00	0.82
2023-12-31	-16.11	-0.01	0.85
2023-09-30	-17.37	-0.01	-0.11
2023-06-30	-20.30	-0.01	1.47
2023-03-31	-20.91	-0.01	3.00
2022-12-31	-20.83	-0.01	3.00
2022-09-30	-20.21	-0.01	3.84
2022-06-30	-19.45	-0.02	5.21
2022-03-31	-21.75	0.05	3.69
2021-12-31	-18.54	-0.03	21.74
2021-09-30	-15.14	-0.07	32.20
2021-06-30	-11.06	-0.11	29.24
2021-03-31	-8.69	-0.17	47.55
2020-12-31	-7.93	-0.10	29.50
2020-09-30	-7.90	-0.05	18.11

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is 1.38.
The p/tbv for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is 1.38.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		1.38	1.38
2025-03-31		-75.94	-75.94
2024-12-31		-2.37	-2.37
2024-09-30	-0.12	2.04	2.04
2024-06-30	-0.13	-1.13	-1.13
2024-03-31		4.34	4.34
2023-12-31	-0.09	0.52	0.52
2023-09-30	-0.19	0.86	0.86
2023-06-30	-0.32	0.73	0.73
2023-03-31	-0.34	0.46
2022-12-31		0.38	0.38
2022-09-30		0.62	0.62
2022-06-30	-0.55	0.32	0.32
2022-03-31	-1.62	0.82	0.82
2021-12-31	-2.37	0.94	0.94
2021-09-30	-3.57	1.13	1.13
2021-06-30	0.00
2021-03-31	-1.70	0.38	0.38
2020-12-31	-1.46	0.37	0.37
2020-09-30	-1.21	0.39	0.39

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -10.04.
The ebit (3y)/ev for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -24.28.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-10.04	-24.28
2025-03-31	-0.22	-0.31
2024-12-31	23.25	32.94
2024-09-30	5.13	6.10
2024-06-30	73.20	79.81
2024-03-31	34.46	33.36
2023-12-31	7.81	6.47
2023-09-30	4.94	3.93
2023-06-30	6.87	5.53
2023-03-31	2.32	1.85
2022-12-31	1.53	1.13
2022-09-30	2.27	1.69
2022-06-30	1.26	0.86
2022-03-31	3.79	2.42
2021-12-31	13.72	9.00
2021-09-30	-3.12	-2.21
2021-06-30
2021-03-31	0.42	0.34
2020-12-31	0.46	0.43
2020-09-30	0.68	0.65

Management Effectiveness

The roa for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -1.02.
The roe for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -8.36.
The roic for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -2.72.
The croic for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is 0.21.
The ocroic for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -3.50.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-1.02	-8.36	-2.72	0.21	-3.50
2025-03-31	-2.18
2024-12-31	-1.53	-22.13
2024-09-30	-1.41	-4.02	-17.44	-4.15	-11.47
2024-06-30	-0.89	-1.94
2024-03-31	-0.82	-1.45	-35.02	-23.24	-25.02
2023-12-31	-0.80	-1.12	-5.63	-4.03	-3.95
2023-09-30	-0.67	-0.79	-4.57	-3.64	-3.90
2023-06-30	-0.65	-0.76	-4.57	-3.64	-3.90
2023-03-31	-0.54	-0.64	-2.24	-1.78	-2.04
2022-12-31	-0.42	-0.46	-0.86	-0.74	-0.91
2022-09-30	-0.42	-0.46	-0.86	-0.74	-0.91
2022-06-30	-0.42	-0.45	-0.63	-0.48	-0.64
2022-03-31	-0.36	-0.39	-0.59	-0.55	-0.65
2021-12-31	-0.45	-0.49	-0.51	0.08	-0.37
2021-09-30	-0.60	-0.56	-0.40	0.41	-0.26
2021-06-30	-0.47	-0.51	-0.31	0.41	-0.25
2021-03-31	-0.82	-1.03	-0.22	0.79	-0.18
2020-12-31	-0.55	-0.72	-0.25	0.63	-0.23
2020-09-30	-0.47	-0.57	-0.31	0.40	-0.31

Gross Margins

The gross margin for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is 1.00.
The net margin for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -596.21.
The operating margin for Cyclacel Pharmaceuticals, Inc. as of June 30, 2025 is -906.07.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	1.00	-596.21	-906.07
2025-03-31	1.00	-181.50	-209.95
2024-12-31	1.00	-181.50	-209.95
2024-09-30	1.00	-218.82	-252.55
2024-06-30	1.00	-43.87	-50.09
2024-03-31	1.00	-53.70	-60.60
2023-12-31	1.00	-63.67	-74.39
2023-09-30	1.00	-63.72	-76.57
2023-06-30		-63.72	-76.57
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30